Feasibility Trials for First Interventional Neuromodulation Platform

02 July 2020 | Australia, United States
The study is the first clinical trial to evaluate the safety and efficacy of the Stentrode, the first interventional neuromodulation platform. This technology is designed to translate brain activity from the inside of a blood vessel, and is being explored for its potential to enable hands-free control of devices for people with upper limb paralysis.
You are not logged in. For existing users, please login to learn more about this premium content. For new users, please register with idtechex.com or use the links below for more details about premium content from IDTechEx.

Subscription Benefits


A subscription from IDTechEx allows you to access our full body of research content on emerging technologies, including market, technology and company data, alongside direct engagement with our expert analysts.
Subscription content includes:
  • Market research reports
  • Forecasts
  • Premium articles
  • Company profiles
  • Industry digests
  • Webinars
  • Innovation maps
  • Event summaries and write-ups